These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 30968417)

  • 41. Screening blood-borne virus among incarcerated inmates.
    Chong VH
    Int J STD AIDS; 2008 Nov; 19(11):795. PubMed ID: 18931282
    [No Abstract]   [Full Text] [Related]  

  • 42. Demonstration of Near-Elimination of Hepatitis C Virus Among a Prison Population: The Lotus Glen Correctional Centre Hepatitis C Treatment Project.
    Bartlett SR; Fox P; Cabatingan H; Jaros A; Gorton C; Lewis R; Priscott E; Dore GJ; Russell DB
    Clin Infect Dis; 2018 Jul; 67(3):460-463. PubMed ID: 29538639
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regions.
    Rusch U; Robbins S; Razavi H; Vernazza P; Blach S; Bruggmann P; Müllhaupt B; Negro F; Semela D
    Swiss Med Wkly; 2019 Jan; 149():w14694. PubMed ID: 30673118
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevalence and clinical significance of GB virus type C/hepatitis G virus coinfection in patients with chronic hepatitis C undergoing antiviral therapy.
    Hofer H; Aydin I; Neumueller-Guber S; Mueller C; Scherzer TM; Staufer K; Steindl-Munda P; Wrba F; Ferenci P
    J Viral Hepat; 2011 Jul; 18(7):513-7. PubMed ID: 20565572
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Is the end of chronic hepatitis C virus infection in sight?
    McCaughan GW
    Med J Aust; 2012 Jun; 196(10):614. PubMed ID: 22676864
    [No Abstract]   [Full Text] [Related]  

  • 46. A policy analysis exploring hepatitis C risk, prevention, testing, treatment and reinfection within Australia's prisons.
    Lafferty L; Wild TC; Rance J; Treloar C
    Harm Reduct J; 2018 Aug; 15(1):39. PubMed ID: 30075728
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prisons face hep C-treatment funding crisis.
    Webster P
    CMAJ; 2016 Feb; 188(3):178-179. PubMed ID: 26783333
    [No Abstract]   [Full Text] [Related]  

  • 48. Hepatitis C Treatment in Prisons - Incarcerated People's Uncertain Right to Direct-Acting Antiviral Therapy.
    Daniels AM; Studdert DM
    N Engl J Med; 2020 Aug; 383(7):611-613. PubMed ID: 32786186
    [No Abstract]   [Full Text] [Related]  

  • 49. Treatment for hepatitis C virus infection among current injection drug users in Australia.
    Matthews G; Kronborg IJ; Dore GJ
    Clin Infect Dis; 2005 Apr; 40 Suppl 5():S325-9. PubMed ID: 15768342
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Treatment of hepatitis C in intravenous drug users].
    Filoche B
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B252-6. PubMed ID: 12180298
    [No Abstract]   [Full Text] [Related]  

  • 51. The comparison of chronic hepatitis C treatment outcome between intravenous drug users and non-intravenous drug users.
    Bojovic K; Simonovic J; Katanic N; Milosevic I; Pesic I; Delic D; Svirtlih N; Jevtovic DJ
    Biomed Pharmacother; 2013 Jul; 67(6):517-20. PubMed ID: 23639229
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prevalence and features of chronic viral hepatitis and HIV coinfection in Italian prisons.
    Stasi C; Silvestri C; Fanti E; Di Fiandra T; Voller F
    Eur J Intern Med; 2016 Oct; 34():e21-e22. PubMed ID: 27189044
    [No Abstract]   [Full Text] [Related]  

  • 53. Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting?
    Gountas I; Sypsa V; Anagnostou O; Martin N; Vickerman P; Kafetzopoulos E; Hatzakis A
    Addiction; 2017 Jul; 112(7):1290-1299. PubMed ID: 28107585
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Elimination on the agenda for hepatitis C.
    Burki T
    Lancet Infect Dis; 2014 Jun; 14(6):452-3. PubMed ID: 24971446
    [No Abstract]   [Full Text] [Related]  

  • 55. Prevalence of hepatitis C and pre-testing awareness of hepatitis C status in 1500 consecutive PWID participants at the Stockholm needle exchange program.
    Kåberg M; Hammarberg A; Lidman C; Weiland O
    Infect Dis (Lond); 2017 Oct; 49(10):728-736. PubMed ID: 28574295
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Harm reduction and viral hepatitis C in European prisons: a cross-sectional survey of 25 countries.
    Bielen R; Stumo SR; Halford R; Werling K; Reic T; Stöver H; Robaeys G; Lazarus JV
    Harm Reduct J; 2018 May; 15(1):25. PubMed ID: 29751763
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical management of drug addicts infected with human immunodeficiency virus and hepatitis C virus.
    Khalsa JH; Vocci F
    J Addict Dis; 2008; 27(2):1-10. PubMed ID: 18681186
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Relapse to opioid use after treatment of chronic hepatitis C with pegylated interferon and ribavirin.
    Matthews AM; Fireman M; Zucker B; Sobel M; Hauser P
    Am J Psychiatry; 2006 Aug; 163(8):1342-7; quiz 1479. PubMed ID: 16877644
    [No Abstract]   [Full Text] [Related]  

  • 59. Micro-elimination of HCV as a possible therapeutic strategy: our experience and a review of literature.
    Bojovic K; Simonovic-Babic J; Mijailovic Z; Milosevic I; Jovanovic M; Ruzic M; Cvejic Pasic T; Svorcan P; Petrovic M; Jordovic J
    J Infect Dev Ctries; 2020 Feb; 14(2):117-124. PubMed ID: 32146444
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations.
    Omran D; Alboraie M; Zayed RA; Wifi MN; Naguib M; Eltabbakh M; Abdellah M; Sherief AF; Maklad S; Eldemellawy HH; Saad OK; Khamiss DM; El Kassas M
    World J Gastroenterol; 2018 Oct; 24(38):4330-4340. PubMed ID: 30344418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.